Virtus develops GRT to cure chronic diseases

A research collaboration of Virtus Techno Innovations, a research and development company associated with Mumbai-based Khandelwal Laboratories, Reliance Life Sciences and SRL Ranbaxy, has succeeded in developing a novel nanotechnology-based Gene Repair Therapy (GRT) that can revolutionise treatments for various chronic diseases such as AIDS, cancer, diabetes etc. Apart from curing diseases, it can also help in reversing the ageing process.

Named as Mitsanika, the new GRT therapy activates dead or inactive genes in human body by using water as a medium to absorb the required minerals and metals that can rejuvenate and activate the genes.

The breakthrough was achieved through mimicking the experience of the fetus while floating in the amniotic fluid, said Dr V K Tripathi, chief executive officer of Virtus, who heads a team of 20 scientists who did the research on GRT for over 11 years.

"At present research success in gene repair is confined only to taking out inactive genes and treating it externally and implanting it again to cure diseases. This is available only in the west and costs at least Rs 20 crore per patient," said Tripathi.

The process has been applied for patenting in India, the US and a couple of other countries.

The human body has around 90,000 various genes dormant under the skin. More than 90 per cent of the genes are inactivated after the age of 25, resulting in ageing and diseases due to lack of essential 82 minerals (sea "� salts), fatty acids (omega 6 and 9), glucose and fructose.

There are no medicines or supplement used in GRT therapy, which is done in consultation with the doctor of the patient.

In this simple treatment method, the patient has to be in a temperature and Ph value-controlled bathtub for one hour daily with all the deficit minerals and fatty acids, elaborated the scientists.